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Obesity shows preserved plasma 
proteome in large independent 
clinical cohorts
Ornella Cominetti1, Antonio Núñez Galindo1, John Corthésy1,2, Armand Valsesia3, 
Irina Irincheeva3,9, Martin Kussmann1,10, Wim H. M. Saris4, Arne Astrup5, Ruth McPherson6, 
Mary-Ellen Harper7, Robert Dent8, Jörg Hager3 & Loïc Dayon  1
Holistic human proteome maps are expected to complement comprehensive profile assessment of 
health and disease phenotypes. However, methodologies to analyze proteomes in human tissue 
or body fluid samples at relevant scale and performance are still limited in clinical research. Their 
deployment and demonstration in large enough human populations are even sparser. In the present 
study, we have characterized and compared the plasma proteomes of two large independent cohorts of 
obese and overweight individuals using shotgun mass spectrometry (MS)-based proteomics. Herein, we 
showed, in both populations from different continents of about 500 individuals each, the concordance 
of plasma protein MS measurements in terms of variability, gender-specificity, and age-relationship. 
Additionally, we replicated several known and new associations between proteins, clinical and 
molecular variables, such as insulin and glucose concentrations. In conclusion, our MS-based analyses 
of plasma samples from independent human cohorts proved the practical feasibility and efficiency 
of a large and unified discovery/replication approach in proteomics, which was also recently coined 
“rectangular” design.
In the very recent years, technology improvements have induced an important paradigm shift for biomarker 
discovery in plasma (as well as in other body fluids and tissues) using mass spectrometry (MS)-based proteom-
ics. Moving from a “triangular” to a “rectangular” approach1, we and others have been innovating the clinical 
proteomic discovery study design from limited sample sizes to much larger cohorts of individuals2–5. Common 
proteomic strategies have applied a “triangular” or funnel design where initial discoveries are obtained on few 
samples (typically tens), followed by replication and validation of biomarker candidates on increasing numbers 
of samples (from typically hundreds to thousands). While technical constraints in sample preparation, liquid 
chromatography (LC) tandem MS (MS/MS) analysis, and bioinformatics have shaped such strategies, new devel-
opments in all those areas allow today deeper proteome coverage with higher throughput, offering new possibil-
ities to design proteomic studies. Larger cohorts of human biospecimens (from typically hundreds to thousands) 
can now be studied with measurements of several hundreds to a thousand of proteins in plasma for instance. In a 
review, Geyer et al. recently used the “rectangular” adjective to conceptualize a clinical study design where both 
proteomic discovery and validation are performed similarly and on the same large enough number of samples 
and protein analytes1. Practical demonstration of such a concept is however still lacking. Here, we present one of 
the first examples of such analyses of two large independent cohorts using MS-based proteomics.
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Importantly, sample size has been often overlooked in proteomic studies. Several groups have argued that 
such a shortcut represents a serious caveat that has mostly dampened the proteomic field to translate protein 
biomarker discoveries into tools of clinical utility6,7. In order not to lag behind expectations on the rate of transfer 
of candidates into the clinics, there is a need to generate knowledge and (candidate) markers that have a better 
chance to be confirmed afterwards. We have argued that the study of larger cohorts of individuals with proteom-
ics from the initial discovery phase is expected to provide the required statistical power to achieve such goals3. In 
view of the inter-individual variability, typically hundreds to thousands of samples need to be analyzed, resulting 
from hundreds of subjects at different time points. With our two large proteomic datasets, we further emphasize 
in this study the relevance of sample size.
To the best of our knowledge, we have gathered the largest combined discovery/validation plasma proteomic 
studies performed so far with untargeted MS. We have measured and report on two independent cohorts cumu-
lating more than a thousand obese or overweight individuals who followed caloric restriction programs to lose 
weight; it represents a total of nearly 1500 plasma samples analyzed. In the current work, we provide about 
500 unreported proteome profiles of plasma samples collected from obese individuals in clinical practice. As a 
result, we are able to assess the practical feasibility and efficiency of a “rectangular” design for clinical proteomic 
research, with emphasis on sample size relevance.
Results
Study design and proteomic workflow. We performed proteomic profiling of nearly 1500 plasma 
samples belonging to almost one thousand obese and overweight subjects from different countries in the world 
(Fig. 1A; demographics of the cohorts is presented in Table 1). For that, we used a highly automated shotgun 
MS-based proteomic workflow relying on isobaric labeling quantification8 (Fig. 1B). The first cohort under study 
was composed of 577 overweight and obese patients of the Weight Management Clinical program of The Ottawa 
Hospital; those patients underwent low calorie diet (LCD) to reduce their weight during a period of 6 to 12 weeks 
(see Experimental Procedures for a detailed description). Throughout this manuscript, we refer to cohort C1 to 
designate this cohort from Canada with plasma samples available at baseline (i.e., before intervention; Fig. 1A). 
The second investigated cohort pertained to the European DiOGenes study9. It was composed of 425 overweight 
and obese participants who followed 8 weeks of controlled LCD, then randomized into 6 months of weight main-
tenance phase. We refer to the DiOGenes cohort as C2A at baseline and as C2B after both weight loss and main-
tenance (Fig. 1A). Plasma samples were available at both time points and proteomic profiles had been previously 
acquired for differential analysis during the DiOGenes intervention5. The main purpose of the present work 
aimed at comparing the plasma proteome profiles of C1 (data never presented before) and C2A (i.e., at baseline), 
representative of overweight and obese phenotypes (Fig. 1C). Demographics and clinical characteristics of the 
cohorts are detailed in Table 1. C1 is composed of more obese subjects than C2. As expected then, fasting insulin 
levels are higher in C1 than in C2 and they are higher in males versus females for both cohorts.
Following the proteomic workflow depicted in Fig. 1B that relies on isobaric tagging for sample multiplex-
ing, LC-MS/MS was performed in duplicate for a total of 843 LC-MS/MS analyses (raw data are available at 
ProteomeXchange; see Experimental Procedures). We identified in total 507 proteins in C1 and 364 proteins in 
C2A and C2B. Of those, 299 and 182 proteins were constantly quantified (i.e., proteins with less than 30% missing 
quantitative data points) in C1 and in C2A/B, respectively. It resulted in an overlap between the cohorts of 179 
quantified proteins for comparison. The baseline datasets (i.e., C1 and C2A) achieved a data completeness of 
97.38% for 179 proteins measured in 1002 individuals. The quantitative data exhibited an overall normal distri-
bution (Fig. 2A).
The number of identified proteins per sample was on average 337 (±21) for C1 and 213 (±19) for C2A/B in 
duplicate LC-MS/MS analyses (Fig. 2B; samples of C2A and C2B were analyzed together with LC-MS/MS after 
sixplex isobaric labeling and sample pooling as previously reported)5. Plasma sample collection, quality, and 
integrity in each cohort may have influenced this proteome coverage difference, as the exact same proteomic 
workflow was applied for C1, measured here, and C2A/B, measured previously. Quantitative precision of a spiked 
internal standard (i.e., bovine β-lactoglobulin (LACB)) in all samples was below 12% in both datasets. Overall, 
this last metric confirmed the quality of the quantitative data before their further exploration, in one of the largest 
combined plasma proteomic dataset ever generated using LC-MS/MS (i.e., ~ 1560 individual plasma samples 
together with ~ 880 plasma pools).
Replication of the variability of plasma proteomes. We assessed the variability of the proteins 
between both C1 and C2A/B cohorts. We found a very high correlation (Pearson correlation coefficients >0.76) 
between the measurement variability of the proteins among the cohorts (Fig. 2C–E), despite C1 and C2A/B 
data belonging to different and heterogeneous populations (see Experimental Procedures). On top, difference 
in sample collection was present (see also Experimental Procedures) and proteomic analyses were performed 
independently in two different exercises distant from several months for C1 and C2A/B despite using the same 
equipment and workflow.
C-reactive protein (UniProtKB entry name: CRP) appeared consistently as one of the plasma proteins 
with highest variability (Fig. 2C–E). This observation could be because these populations were composed of 
either obese or overweight individuals with varying degrees of inflammation, often transient, for which CRP 
is a known marker. While CRP levels are strongly associated with body weight10, reduced with weight loss and 
increased with weight gain, they are also affected by concomitant treatments including statins and nonsteroidal 
anti-inflammatory drugs. Among others, CRP measured with LC-MS/MS was also previously shown to strongly 
vary between individuals4, as an acute phase marker for inflammation in the body. Some proteins presenting high 
variability might be more deeply studied as this degree of variance can be attributed to the randomness of the 
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measurements (biological and technical) but also to very different underlying phenotypes in the studied popula-
tions (see next section on gender specificity).
Among the least variable proteins between individuals, we found several members of the coagulation and 
complement cascades. Few of those have been previously shown to be also stable overtime in the plasma pro-
teome11. Antithrombin-III (ANT3), kininogen-1 (KNG1), complement C1r subcomponent-like protein (C1RL), 
coagulation factor X (FA10), prothrombin (THRB), complement factor I (CFAI), hemopexin (HEMO), coag-
ulation factor IX (FA9), and selenoprotein (SEPP1) were among the least variable proteins in all three cohorts 
(i.e., 9/14 proteins, representing 64% of the lists of least variable proteins). This constitutes a very strong result on 
Figure 1. Schematic diagram of (A) obese/overweight cohorts’ characteristics, (B) experimental workflow 
and (C) study design encompassing the analysis of nearly 1500 individual plasma samples. C1 is a cohort of 
577 overweight and obese patients of the Weight Management Clinical program of The Ottawa Hospital. C2 
represents a cohort of 425 overweight and obese participants of the European study DiOGenes measured 
at baseline and at the end of a dietary intervention. Proteomic analysis was performed as previously 
described (see Experimental Procedures), combining immunodepletion, protein digestion, peptide isobaric 
labeling (with sixplex technology), and LC-MS/MS analysis. In particular, the last four steps of the sample 
preparation in (B) were performed in an automatic robotic platform as previously described (see Experimental 
Procedures).
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the capabilities of MS-based proteomic profiling to provide reliable measurements in independent large clinical 
cohorts. Comparing only C1 and C2A (i.e., at baseline), ANT3, KNG1, C1RL, FA10, THRB, complement C1r 
subcomponent (C1R), CFAI, HEMO, carboxypeptidase N subunit 2 (CPN2), FA9, α-1B-glycoprotein (A1BG), 
and SEPP1 were the common less variable proteins in plasma samples (12 of the 14 less variable proteins, i.e., 
86%, in C1 are also among the 14 less variable proteins in C2A).
In general, the standard deviations (SDs) for the commonly measured proteins were smaller in C1 than in C2. 
This could be explained by the fact that the C1 population was more uniform (see Supplementary Material); on 
top, there was only one collection center in one country (i.e., Ottawa, Canada), unlike C2, with its seven collection 
centers considered here, each in a different European country (see Experimental Procedures), and with a center 
effect previously identified3.
Plasma proteome and gender. As shown in our previous work3, a few proteins showed differences 
between females and males in C2A and C2B (Fig. 2G,H). The three gender-specific proteins identified, namely 
pregnancy zone protein (PZP), sex hormone-binding globulin (SHBG), and apolipoprotein C-II (APOC2) repli-
cated also as gender-specific proteins in the C1 cohort (Fig. 2F). The observed high variability of PZP and APOC2 
(Fig. 2C-E) might be therefore mostly driven by the important differences between males and females. We believe 
assessing those gender proteins can be a valuable quality check of human plasma proteomic data.
CRP (Fig. 2F–H) was measured at higher levels in males than in females in some studies12–14. However, those 
results may be considered as inconclusive, as other studies showed opposite results15,16 or no significant differ-
ence17. As in both C1 and C2A cohorts, men presented higher abdominal fat (Table 1), the observed differences 
in CRP levels may result from a more profound acute inflammation state in the male than in the female subjects.
It is a known fact that several covariates affect the measurements of proteins in biological fluids such as human 
plasma. Those confounders should always be considered when designing clinical research studies. We performed 
a comparative analysis of these possible confounders in our study. Following a similar approach to that of Enroth 
et al.18, we displayed significant effects of anthropometric variables on the proteins. The figure and a breakdown 
of this analysis per cohort is presented in the Supplementary Material (Supp. Figs S1 and S2). Results of statistics 
are given in Tables 2–4 for gender, age, and body mass index (BMI), respectively.
On top of the already identified differential proteins between genders by comparing their aver-
age between males versus females (i.e., PZP, SHBG, APOC2, and CRP), using a linear model approach, 
we determined additional gender-associated proteins such as leucine-rich alpha-2-glycoprotein (A2GL), 
afamin (AFAM), corticosteroid-binding globulin (CBG), ceruloplasmin (CERU), fetuin-B (FETUB), 
phosphatidylinositol-glycan-specific phospholipase D (PHLD), and proline-rich acidic protein 1 (PRAP1) 
(Table 2). Among them, APOC2, AFAM, PHLD, and PRAP1 showed a negative association with the gender 
parameter (i.e., are higher in males than in females). PZP presented the strongest positive association with the 
gender parameter (i.e., largest estimate in Table 2) and APOC2 the strongest negative association. The higher 
presence of APOC2 in plasma of males has already been reported19. Those proteins should therefore be con-
sidered with caution when proposed as candidate biomarkers as they might be strongly influenced by gender. 
Several of these proteins had already been identified to show gender dimorphism in different cohorts and using 
different proteomic measurement techniques. Such is the case for SHBG and FETUB being higher in females than 
in males20, PZP21 and CBG22, also higher in females than in males, and PHLD higher in males than in females21.
Plasma proteome and age. The proteins that are significantly associated with age in the three cohorts 
were C4b-binding protein alpha chain (C4BPA), C4b-binding protein beta chain (C4BPB), cartilage acidic pro-
tein 1 (CRAC1), EGF-containing fibulin-like extracellular matrix protein 1 (FBLN3), histidine-rich glycoprotein 
(HRG), plasma protease C1 inhibitor (IC1), lumican (LUM), N-acetylmuramoyl-L-alanine amidase (PGRP2), 
Cohort C1 C2
Variable Females Males Females Males
N 403 174 273 152
Age [years] 48 ± 12 50 ±11 42 ± 6 43 ± 6
BMI at baseline [kg/m2] 44.80 ± 7.44 44.94 ± 7.36 33.88 ± 4.70 33.83 ± 4.49
BMI after intervention [kg/m2] 40.93 ± 6.90 40.29 ± 6.45 30.48 ± 4.39 30.44 ± 4.21
WC at baseline [cm] 163.53 ± 6.58 177.82 ± 12.96 103.59 ± 11.72 113.06 ± 11.61
WC after intervention [cm] 115.41 ± 13.14 128.56 ± 14.76 94.16 ± 11.25 101.15 ± 11.24
Fasting insulin [mIU/L derived] 18.72 ± 17.74 26.34 ± 20.81 10.90 ± 10.90 13.46 ± 11.99
Fasting glucose [mmol/L derived] 5.87 ± 2.16 6.92 ± 2.77 5.03 ± 0.63 5.25 ± 0.48
Cholesterol, fasting [mmol/L] 4.736 ± 0.98 4.07 ± 1.00 4.73 ± 0.97 4.97 ± 1.12
HDL, fasting [mmol/L] 1.21 ± 0.29 0.97 ± 0.22 1.30 ± 0.33 1.04 ± 0.24
LDL, fasting [mmol/L] 2.77 ± 0.87 2.29± 0.90 2.90 ± 0.85 3.18 ± 0.97
Triglycerides, fasting [mmol/L] 1.72 ± 0.97 1.92 ± 1.08 1.21 ± 0.56 1.64 ± 0.72
Table 1. Demographics and clinical characteristics of the Canadian C1 and European C2 cohorts. Data are 
presented as mean ± standard deviation (SD); N: Number of individuals; BMI: Body mass index; WC: Waist 
circumference; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.
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Figure 2. (A) Distributions of Log2 of the protein ratio fold-changes with respect to pool samples and (B) 
number of proteins identified per sample for the three cohorts (i.e., C1, C2A, and C2B). Scatter plots for 
individual protein SD obtained for the C1 cohort versus the C2 cohorts, (C) C2A and (D) C2B, and between 
the two collection days in C2 (E). The least variable - on average between the measurements - (green color) and 
most variable (red to orange color) commonly quantified proteins between the cohorts are displayed. Gender 
differences in the (F) C1 and (G) C2A, and (H) C2B. Mean relative quantitative proteins values, measured as 
the Log2 of the protein ratio fold-changes with respect to pool samples. The gray square represents the area 
for values comprised within the estimated technical variance. Only proteins with a high mean fold change 
difference between genders are shown in color. The full list of significant gender-specific proteins, are presented 
in Table 2. For C2, data were averaged over seven European collection centers.














PZP 1.480 1.90E-46 1.370 5.07E-24 1.422 5.62E-23
SHBG 0.408 2.87E-07 0.684 1.41E-17 0.734 1.49E-20
APOC2 −0.501 6.42E-05 −0.711 1.38E-10 −0.539 1.29E-06
CRP 0.580 5.23E-05 0.384 3.94E-02 0.591 1.98E-03
A2GL 0.115 1.54E-02 0.286 1.18E-07 0.308 5.81E-09
AFAM −0.154 2.54E-04 −0.150 1.51E-02 −0.125 4.54E-02
CBG 0.179 2.77E-03 0.175 3.47E-02 0.275 1.61E-03
CERU 0.211 9.55E-08 0.211 6.70E-03 0.358 9.84E-07
FETUB 0.107 3.07E-02 0.190 1.08E-02 0.182 3.21E-02
PHLD −0.207 2.06E-07 −0.257 3.45E-04 −0.187 2.96E-02
PRAP1 −0.211 2.13E-05 −0.201 8.94E-03 −0.176 4.42E-02
Table 2. Proteins significantly associated with gender for the three cohorts.
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and metalloproteinase inhibitor 2 (TIMP2). All these proteins were positively associated with age (positive values 
in the estimates of Table 3). The age of the population ranged between 16 and 81 years for C1, and 16 and 63 years 
for C2A/B. It is reasonable to think that if the C2 cohorts also had subjects in the last two decades of the age range 
of C1, when important physiological and protein changes may occur, more proteins could have been identified to 
be commonly influenced by age.
Plasma proteome and BMI. Among the BMI-protein significant associations in these three obese/over-
weight datasets, we consistently observed complement factor B (CFAB), complement factor H (CFAH), CFAI, 
CRP, PRAP1, as well as the calprotectin complex formed by proteins S100-A8 (S10A8) and S100-A9 (S10A9). 
All these proteins were positively associated with CRP presenting by far the strongest association with BMI (i.e., 
largest estimate in Table 4 in each cohort).
Plasma proteome and other clinical variables. We then looked at markers of obesity and associated 
co-morbidities and directly compared the results of C1 and C2A (i.e., baseline measurements). Additional results 
for the C2B dataset are provided in the Supplementary Material, Supp. Fig. S3. We also investigated whether 
gender or age influenced these results and verified that there were only minor differences after correcting the 
protein measurements for age and gender (see the results in Supp. Fig. S4 of the Supplementary Material). As a 
matter of fact, the association significance was mainly decreased for protein correlations with glucose and HDL 
levels. We observed good agreements of the clinical variable-protein associations between both C1 and C2A 
cohorts (Supplementary Material, Supp. Fig. S5). More precisely, we observed an average agreement of 60% 
between the significantly associated proteins in the cohorts.
In particular, several proteins significantly associated with insulin and glucose levels in blood (Fig. 3):
•	 Fasting insulin. PRAP1 was found to strongly correlate (positively) with fasting insulin for both C1 and C2A 
datasets (Fig. 3A,B), also when accounting for gender and age (Supplementary Material, Supp. Fig. S4C,D). 
Other proteins, also with positive correlations to fasting insulin for both baseline cohorts were pantethein-
ase (VNN1), AFAM, pigment epithelium-derived factor (PEDF), and galectin-3-binding protein (LG3BP), 
although to a lesser degree than PRAP1. Fasting insulin was correlated positively with a large number of 
proteins in C2A (Fig. 3B).
•	 Fasting glucose. High positive correlations and some negative correlations of some proteins were found for 
C1 data with fasting glucose, specifically cathepsin D (CATD) (Fig. 3C). CATD has been shown to be asso-
ciated with indices of insulin-resistance homeostasis model assessment (i.e., HOMA computed from fasting 
glucose levels) in newly diagnosed type 2 diabetes (T2D) patients. For C2A (Fig. 3D), the correlations were 
very small yet significant. SHBG was found in the two cohorts as negatively correlated with fasting glucose 
while APOC2 was positively correlated with fasting glucose.














CFAB 0.006 3.74E-02 0.017 3.48E-03 0.012 4.04E-02
CFAH 0.006 1.57E-02 0.022 2.20E-03 0.020 2.18E-03
CFAI 0.006 6.67E-03 0.015 6.70E-03 0.012 3.15E-02
CRP 0.059 4.05E-12 0.111 2.57E-11 0.086 1.29E-06
PRAP1 0.007 4.99E-02 0.038 5.50E-08 0.021 1.67E-02
S10A8 0.013 1.55E-02 0.045 1.07E-06 0.024 3.69E-02
S10A9 0.018 5.65E-04 0.044 3.34E-07 0.031 1.23E-03
Table 4. Proteins significantly associated with BMI for the three cohorts.














C4BPA 0.010 2.12E-05 0.018 2.63E-02 0.021 6.64E-03
C4BPB 0.013 1.17E-05 0.023 2.47E-02 0.024 2.87E-02
CRAC1 0.013 2.35E-09 0.017 1.51E-02 0.022 3.17E-03
FBLN3 0.011 5.06E-15 0.012 1.51E-02 0.012 1.11E-02
HRG 0.013 1.30E-06 0.023 9.76E-03 0.023 8.17E-03
IC1 0.006 1.26E-03 0.020 1.56E-02 0.027 1.98E-03
LUM 0.014 8.36E-18 0.010 4.61E-02 0.013 2.87E-03
PGRP2 0.004 6.20E-03 0.011 2.94E-02 0.013 8.46E-03
TIMP2 0.007 3.44E-07 0.011 2.41E-02 0.014 1.11E-02
Table 3. Proteins significantly associated with age for the three cohorts.
www.nature.com/scientificreports/
7SCIENTIFIC REPORtS |         (2018) 8:16981  | DOI:10.1038/s41598-018-35321-7
On the subsequent analyses, we further focused only on the baseline cohorts (i.e., C1 and C2A) in order to iden-
tify the commonalities between these two large obese/overweight populations. In the Supplementary Material, Supp. 
Figs S6 and S7, complementary results for the C2B dataset after the dietary intervention are provided.
Plasma proteins and their association maps in obesity and overweight. With our large and unique 
MS-based proteomic datasets, we then deciphered an interaction map of the plasma proteins in obese/overweight 
individuals. Large numbers of pairs or groups of plasma proteins showed high correlation between them, given 
their participation in same complexes, or the same signaling pathways, biological processes or other types of 
interactions. Studying the frequency of correlation coefficients in the datasets, we observed that the distributions 
differed between the C1 and C2A cohorts (Fig. 4A).
With chord diagrams, we represented the significant correlations between any pair of proteins in both C1 and 
C2A (Fig. 4B,C). Results for these analyses including C2B are shown in Supp. Figs S6 and S7. Inter-protein corre-
lations in C1 (Fig. 4B) were for the vast majority smaller than in C2A (Fig. 4C). As expected, we observed strong 
repeated associations between protein components of same complexes (e.g., calprotectin composed of S10A8 and 
S10A9; membrane attack complex composed of complement component C8 alpha chain (CO8A), complement 
component C8 beta chain (CO8B) and complement component C8 gamma chain (CO8G); and C4BPA composed 
of 7 identical C4BPA chains and one unique C4BPB chain), members of the complement system, or proteins from 
the same families (e.g., inter-alpha-trypsin inhibitor heavy chains (ITIHs)).
All the strongest correlations were positive. The largest negative correlations were below 0.40, while the high-
est positive correlation were above 0.90. This was likely the case because strong positive correlations may be due to 
strong physical binding of proteins, while anti-correlations between proteins might be caused by subtle regulatory 
relationships for instance.
In Fig. 4D–F, the chord diagrams of the common interactions found in both C1 and C2A are represented, 
highlighting the plasma protein-protein relationships at different levels of stringency. The proteins of the comple-
ment system were here again consistently highly correlated with each other in plasma. Interestingly, another set 
of proteins composed of calmodulin (CALM), SH3 domain-binding glutamic acid-rich-like protein 3 (SH3L3), 
thymosin beta-4 (TYB4), cofilin-1 (COF1), profilin-1 (PROF1), and transgelin-2 (TAGL2) also clearly emerged 
(Fig. 4D). Those interactions suggest that some protein measurements might be used as proxy of other proteins 
in plasma. Applying less stringency (Fig. 4E,F), some other specific associations appeared, somehow independent 
of the previously mentioned (e.g., S10A8 and S10A9, complement C1s subcomponent (C1S) and C1R, and ITIH1 
and ITIH2).
Relevance of sample size in MS-based proteomic profiling of human plasma. In order to observe 
how the sample size of our cohorts contributed to the number and validity of associations revealed, we repeated 
the previous protein-protein correlation analysis in smaller subsets of these cohorts. For this, randomly, we 
removed an increasing percentage of the subjects from the two cohorts C1 and C2A and observed the average 
results of the number of associations identified. To derive a robust estimate of the number of correlations among 
the proteins, we performed bootstrap and repeated 100 times this approach23,24. As expected, for increasingly 
large sample sizes, the average stabilizes and the range becomes narrower (law of large numbers)25.
In Fig. 4G–I, for small datasets (less than 25 subjects considered) the number of common significant interac-
tions (adjusted p-value ≤ 0.05) was roughly one third of the ones found for larger sample sizes, exemplifying that 
many plasma discovery proteomic results reported so far are underpowered indeed. In our study, the variability 
on the number of identified interactions decreased when the cohort size increased. For example, in our data, to 
obtain SD smaller than 10% on the number of common interactions, over 100 subjects were needed. The relative 
variability decreased as the stringency threshold decreased (from Fig. 4G to Fig. 4I). Therefore, to obtain high 
Figure 3. Clinical variable-protein correlations for C1 and C2A, shown as volcano plots. (A,B) Fasting insulin 
[mIU/L derived], (C,D) fasting glucose [mmol/L derived]. The horizontal dashed line in each plot represents 
the threshold of significance of adjusted p-value ≤ 0.05 and the vertical dotted lines represent the limits of 
−0.2 and 0.2 of the Spearman correlation coefficients. Only the names of the proteins significantly regulated 
are shown, and they are colored if they are significant for both cohorts. Red corresponds to positive correlated 
proteins (i.e., on the right) and in blue are depicted the negatively correlated proteins (i.e., on the left).
www.nature.com/scientificreports/
8SCIENTIFIC REPORtS |         (2018) 8:16981  | DOI:10.1038/s41598-018-35321-7
confidence in the deciphered protein-protein interactions, it is mandatory to deal with sufficiently large cohorts. 
The averaged 11 common interactions for the first point on the left in Fig. 4H,I (which were obtained from 100 
iterations and therefore with more than the actual small numbers of samples indicated in the figures), corre-
sponded to the interactions observed for the most stringent of the thresholds, i.e., the one shown in the last point 
on the right of Fig. 4G. These proteins were so strongly correlated, that even for some small subsets of the cohorts, 
they could potentially be identified (but with the risk of finding together false positive and negative discoveries as 
illustrated by the large SD bars obtained with such small numbers of samples).
Discussions
In this work, we demonstrated that MS is a robust technology for protein biomarker discovery and replication in 
human blood. MS-based proteomic workflows can be used in clinical research studies of large cohorts. In particu-
lar, shotgun proteomics using relative quantification techniques can generate highly consistent and reproducible 
results. It can provide new insights into complex phenotypes4,5 amenable to independent validation, even when 
the samples are analyzed separately.
Figure 4. (A) Histogram of pairwise correlation coefficients for C1 (in green) and C2A (in blue). Chord 
diagrams representing significant correlations between pairs of proteins in (B) C1 (Spearman, R >  0.85) and 
(C) C2A (Spearman R > 0.85). Levels of significance were corrected for multiple testing using the Benjamini-
Hochberg procedure. Chord diagrams representing significant common inter-protein relationships between 
baseline cohorts, C1 and C2A for decreasing stringency: thresholds for Spearman correlation coefficients of (D) 
0.90, (E) 0.85, and (F) 0.80. Number of significant pairs was (D) 11, (E) 28, and (F) 44, respectively. Levels of 
significance were corrected for multiple testing using the Benjamini-Hochberg procedure. Number of common 
significant interactions between the C1 and C2A cohorts after randomly removing a given percentage of their 
total number of subjects for decreasing stringency; thresholds for Spearman correlation coefficients of (G) 0.90, 
(H) 0.85 and (I) 0.80 were used. The dots represent the median value of the number of interactions identified 
among all the iterations, and the bars represent the corresponding SDs. The top x-axis corresponds to the size of 
the C2A cohort, while the bottom x-axis represents the number of subjects in the C1 cohort.
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Our work shows that using a large sample size at the initial discovery phase (hundreds of subjects rather than 
tens), robust proteomic results can be obtained and can be effectively repeated in independent cohorts, potentially 
providing further clinical generalization. Robust replication is demonstrated with proteins specific to gender (that 
can be used for quality check of the data), proteins correlating with clinical parameters and biochemical measures 
relevant to obesity, and proteins associating in peripheral circulation. Through the availability of an extensive 
dataset of about 1500 plasma samples, preserved demographic phenotype is shown in two independent cohorts 
from two continents. Such practice in the proteomic field may increase the chances that identified biomarkers 
translate to other populations and are of clinical utility. The definition and practical demonstration of “rectangu-
lar” studies in proteomics therefore constitute important milestones, enabled by the developments and matura-
tion of MS-based proteomic technologies. Key technological enablers to those larger clinical proteomic discovery 
studies have been multiple in recent years. For instance, automation of proteomic sample preparation26 is required 
to ensure throughput, robustness and accuracy, together with more rapid and more sensitive MS instrumentation. 
Sample multiplexing, via mass labeling for instance, could also represent an important asset8. Improvement and 
automation of data storage, processing, and analysis are also mandatory. All those elements, plus others, when 
combined, are indeed expected to empower MS-based proteomics for the discovery of novel and robust clinical 
biomarkers. In the past few years, we have developed a scalable and integrated proteomic pipeline8. We have 
deployed this workflow to measure a large number of plasma samples from obese and overweight individuals (i.e., 
C2A/B)5,8, and have herein further demonstrated its robustness and potential in clinical research with the analysis 
of an additional independent cohort (i.e., C1).
Importantly, we demonstrate the overall conservation of proteome variability (and stability) between two 
independent cohorts of obese and overweight individuals. This variability could explain in part why validation 
of biomarkers has not been always successful for a number of proteomic studies, often underpowered7,27,28. The 
next step would be to evaluate the reproducibility across laboratories. This important point is being currently 
investigated by different groups29, but would also need to be evaluated using large numbers of samples. Mann 
and co-workers recently showed that in general plasma protein levels tend to vary more between subjects than 
over the time in each subject following a dietary intervention4. Importantly when studying independent cohorts, 
not only the protein data vary between the groups, but also the confounding effects. When studying associations 
between the proteomes and main confounding effects such as age and gender, we again highlighted a remarkable 
consistency in these effects between the datasets.
Obesity is a complex disease and encompasses diverse phenotypes associated with, for instance, a range of 
different degrees of inflammation and multiple associated comorbidities. Analyzing populations of obese indi-
viduals for biomarker identification (either for diagnostic, prognostic, or research purposes) is therefore a very 
challenging task. Our findings, replicated in two independent cohorts, indicate the robustness of our results, even 
more when considering the inherent and noticeable differences of the cohorts, with one (i.e., C1) made of more 
extreme obese patients, from a clinical practice, than the other one (i.e., C2), obtained from a randomized control 
trial. Here again, the large sample size of the cohorts (several hundreds of patients in each) allowed generating 
reproducible observations.
The diagnostic accuracy of current biomarkers in the field of obesity has still not reached accuracies high 
enough to be used in the clinics30. Among current biomarkers used in obesity, there are those that aim at the early 
identification of obesity, its treatment definition, the assessment of the risks of complications, and the evaluation 
of its degree of severity. For instance, adipokines, such as leptin, TNF-alpha and resistin, have a pro-inflammatory 
role and are associated with an increased risk of obesity comorbidities such as T2D and cardiovascular diseases30. 
Adiponectin and omentin, on the other hand, have an anti-inflammatory and cardioprotective role, as well as 
being linked to glycemic control30. Markers for weight loss in obese populations such as CRP, SHBG, SAA pro-
teins, members of the apolipoprotein family and of the complement pathway have been previously reported by 
us and others4,5. Some of these markers have been also associated with clinical parameters linked with obesity. 
In the current study, PRAP1 showed a strong positive correlation with fasting insulin levels (Fig. 3) and triglyc-
erides (Supplementary Material, Supp. Fig. S4M,N). Those newly revealed associations represent new findings 
that should deserve further investigations. Taken together, those markers may enable early identification, proper 
treatment and follow-up of a number of co-morbidities associated with obesity, such as insulin resistance, its 
severity, and dyslipedemia.
While we demonstrated the application of untargeted MS-based shotgun proteomics for the discovery and 
replication of plasma biomarkers in independent cohorts, one limitation of our study was the still limited pro-
teome coverage obtained. The presented data were obtained with hybrid linear ion trap-Orbitrap (LTQ-OT) Elite 
mass spectrometers. From our recent experience, with the latest generation of Tribrid Orbitrap mass spectrome-
ters31 for instance, the human plasma proteome coverage can be drastically improved, which is expected to sup-
port the deployment of our and other untargeted MS-based proteomic strategies in clinical research. Additionally, 
we undertook a stringent filtering approach and discarded a number of proteins based on data missingness (with-
out performing imputation). While there are some recommendations32,33 in other omics fields (e.g., transcriptom-
ics and metabolomics), there is still to date, very little benchmarks and guidelines in proteomics to account for 
and adequately impute missing data34.
Blood proteomes can provide complementary information to traditional clinical measurements. Proteomes 
closely relate to the true physiological state of an individual. Proteins, considered in biological systems and con-
texts, can even better offer therapeutic targets and/or support clinical decision-making. Proteomic profiles can 
give information at different levels that are relevant to both the healthy state and disease status, e.g., obesity/
overweight conditions. We showed the plasma proteome to be representative of diverse clinical parameters 
together. Herein, we demonstrated with real data, the robustness of MS measurements of the plasma proteome. 
Proteomic analysis of two large independent cohorts gave replicable results and provided insights into the obesity 
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phenotype. From these results, we believe that in a foreseeable future, profiles and/or panels of plasma or serum 
protein markers would be available, that can be readily measured in the clinics.
Experimental Procedures
Experimental Design and Statistical Rationale. Description of cohorts. The cohorts, which were com-
pared in this work, were from the Weight Management Clinical program of The Ottawa Hospital (C1) and the 
DiOGenes study (C2) at baseline (C2A) and after weight loss and weight maintenance (C2B). The C2 cohort and 
the subject and sample selection have been previously described3,9.
C1 was initially composed of 2383 overweight and obese patients, who underwent a meal replacement pro-
gram. Patients were monitored for up to 36 weeks, checking their weight, height, blood pressure, at every visit. 
At week 1, they received a battery of biochemistry tests, from lipid profile to fasting insulin, and blood glucose 
determination.
Patients began the program between September 1993 and May 2013 and completed it between 1994 and 2014. 
However, de facto, plasma samples in this study were only from subjects followed at The Ottawa Hospital between 
2003 and 2013.
Exclusion criteria before enrollment included important weight loss before the program, autoimmune dis-
ease, cancer, and previous bariatric surgery. Patients were also excluded after being admitted to the program and 
throughout its duration according to the following criteria:
•	 Non-compliance: admitting not following the meal replacement program, delayed taking the product, eating 
meals or not taking the product, bulimia, binge eating, extended fasting; Non-compliance with exercise, very 
low energy expenditure, wheelchair bound; High number of absences of the monitoring appointments.
•	 Taking anti-diabetic drug and drugs to control glucose, stimulant drugs, diet pills, psychotropics, antidepres-
sants, antipsychotic or anti-epileptic drugs, or immunosuppressant drugs.
•	 Hospitalization and surgeries (gastroplasty, intestinal bypass, bariatric surgery, and others such as angioplasty, 
inguinal hernia repair, hysterectomy).
•	 Complications such as thyroid problems (suppressed or elevated thyroid stimulating hormone (TSH), goitre), 
severe insulin resistance, peripheral oedema, inflammatory bowel disease, Crohn’s disease, blindness, renal 
failure, meningitis, otitis, high stress levels, severe learning and memory problems, traumatic brain injury.
After exclusion, 2032 patients remained in the study, i.e., 1448 females and 584 males.
Questionnaires assessed their physical activity, planned and current, scores and barriers to exercise, as well 
as smoking status (current and previous), alcohol intake (heavy drinker, amount, problem with alcohol intake), 
depression, drugs, and medications taken (such as lowering or increasing blood pressure medication, lipid low-
ering agents, hypertension, topical corticosteroids, beta blockers). For women cyclic, menstrual status and men-
opause comments were recorded.
Before the MS-based proteomic analysis, additional exclusion criteria were considered such as pregnancy 
during study, compliance to weight loss protocol, plasma samples taken under fasting conditions, uses of drug 
affecting weight, abnormal thyroid function and type 1 diabetes. The key criterion was the availability of the 
plasma samples.
For C2A and C2B, the proteomic results were previously reported3. One collection center previously shown to 
present a clear deviation from the other centers3 was excluded from the C2 cohort considered in this study. The 
choice of N was based on the largest available number of samples.
Dataset completeness of proteomic datasets. C1 comprised 577 plasma samples, for whom 507 proteins were 
measured (data matrix completeness of 66.5%). Among these, 154 proteins contained no missing values. In our 
filtered dataset used herein, 299 proteins contained at most 30% missing values, giving a total data matrix com-
pleteness of 94.8%. C2A, on the other hand comprised 425 plasma samples, for whom 364 proteins were meas-
ured (data matrix completeness of 58.4%), 182 of which have a maximum of 30% missing values giving a final 
filtered dataset completeness of 95.4%. For C2B, 373 proteins were measured in 429 plasma samples (data matrix 
completeness of 58.4%), of which 182 contained at most 30% of missing values, giving a final filtered dataset 
completeness of 95.4%. Figures of data completeness can be found in the Supplementary Material (Supp. Fig. S8). 
In total, 327 proteins were found in common between C1, C2A and C2B, and 179 proteins among them had at 
most 30% of missing values. These protein lists and the data tables can be found in the Supplementary Material.
Materials, Sample Preparation and MS Analysis. Materials. Iodoacetamide (IAA), tris(2-carboxyethyl) 
phosphine hydrochloride (TCEP), triethylammonium hydrogen carbonate buffer (TEAB) 1M pH = 8.5, sodium 
dodecyl sulfate (SDS), and LACB from bovine milk were purchased from Sigma (St. Louis, MO, USA). Formic acid 
(FA, 99%) was from BDH (VWR International Ltd., Poole, UK). Hydroxylamine solution 50 wt% in H2O (99.999%) 
was acquired from Aldrich (Milwaukee, WI, USA). Water (18.2 MΩ·cm at 25 °C) was obtained from a Milli-Q 
apparatus (Millipore, Billerica, MA, USA) and acetonitrile from BDH. Trifluoroacetic acid Uvasol® was sourced 
from Merck Millipore (Billerica, MA, USA). The sixplex tandem mass tags (TMTs) were purchased from Thermo 
Scientific (Rockford, IL, USA). Sequencing grade-modified trypsin was procured from Promega (Madison, WI, 
USA). For immuno-affinity depletion of 14 abundant human proteins, multiple affinity removal system (MARS) 
columns, Buffer A, and Buffer B were obtained from Agilent Technologies (Wilmington, DE, USA). Oasis HLB car-
tridges (1cc, 30 mg) were acquired from Waters (Milford, MA, USA) and strong cation-exchange (SCX) solid-phase 
extraction (SPE) cartridges from Phenomenex (Torrance, CA, USA).
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Sample preparation. From 25 µL of each plasma sample (diluted in 75 µL of Buffer A containing 0.0134 mg/
mL LACB and filtered with 0.22 µm filter plate from Millipore), 14 abundant plasma proteins were removed, 
following the manufacturer instructions, with MARS columns and high performance (HP) LC systems (Thermo 
Scientific, San Jose, CA, USA) equipped with an HTC-PAL (CTC Analytics AG, Zwingen, Switzerland) fraction 
collectors. After immunodepletion, samples were snap-frozen. Buffer exchange was performed with Strata-X 33 u 
Polymeric reversed-phase (RP) (30 mg/1 mL) cartridges mounted on a 96-hole holder and a vacuum manifold, 
all from Phenomenex as previously described8. Samples were subsequently evaporated with a vacuum centrifuge 
(Thermo Scientific) and stored at −80 °C. Reduction, alkylation, digestion, TMT sixplex labeling, and SPE sam-
ple purification (Oasis HLB and SCX) were performed on a 4-channels Microlab Star liquid handler (Hamilton, 
Bonaduz, Switzerland) according to a previously reported and validated protocol8. Briefly, each lyophilized sam-
ple was dissolved in 95 µL of TEAB 100 mM and 5 µL of SDS 2%. Next, a volume of 5.3 µL TCEP 20 mM was added 
and incubation was performed for 1 h at 55 °C. A volume of 5.5 µL IAA 150 mM was added (incubation for 1 h in 
the dark). Following this step, enzymatic digestion was performed by addition of 10 µL trypsin at 0.25 µg·µL−1 in 
TEAB 100 mM and incubation overnight at 37 °C. TMT labelling was performed by addition of 0.8 mg sixplex 
TMT reagent in 41 µL CH3CN (incubation for 1 h at room temperature). After reaction, a volume of 8 µL hydrox-
ylamine 5% in H2O was added to each tube to react for 15 min. Samples from a given sixplex TMT experiment 
were pooled together in a new tube (each TMT experiment included four samples and two pool plasma samples 
which were used as biological references for relative quantification of proteins). Pooled samples were further 
purified with Oasis HLB cartridges followed by SCX SPE. The purified pooled sixplex TMT-labeled samples were 
then evaporated to dryness before storage at −80 °C.
LC-MS/MS analysis. The samples were dissolved in 500 µL H2O/CH3CN/FA 96.9/3/0.1 for RP-LC-MS/MS. 
LC-MS/MS was performed on two identical systems composed of a hybrid LTQ-OT Elite and an Ultimate 3000 
RSLC nano system (Thermo Scientific). Proteolytic peptides (injection of 5 µL of sample) were trapped on an 
Acclaim PepMap 75 µm × 2 cm (C18, 3 µm, 100 Å) pre-column and separated on an Acclaim PepMap RSLC 
75 µm × 50 cm (C18, 2 µm, 100 Å) column (Thermo Scientific) coupled to a stainless steel nanobore emitter 
(40 mm, OD 1/32”) mounted on a Nanospray Flex Ion Source (Thermo Scientific). The analytical separation was 
run for 150 min using a gradient that reached 30% of CH3CN after 140 min and 80% of CH3CN after 150 min at a 
flow rate of 220 nL/min. For MS survey scans, the OT resolution was 120000 (ion population of 1 × 106) with an 
m/z window from 300 to 1500. For MS/MS with higher-energy collisional dissociation at 35% of the normalized 
collision energy, ion population was set to 1 × 105 (isolation width of 2), with a resolution of 15000, first mass at 
m/z = 100, and a maximum injection time of 250 ms in the OT. A maximum of 10 precursor ions (most intense) 
were selected for MS/MS. Ions with 1+ and unassigned charge-states were rejected from the MS/MS analysis. 
Dynamic exclusion was set for 60 s within a ± 5 ppm window. A lock mass of m/z = 445.1200 was used. Each 
sample was analyzed in duplicate once on each of the two independent but identical RP-LC-MS/MS platforms. 
The exact same setup and instrumentation were used for both studies (i.e., C1 and C2) with a 15-month interval. 
The mass spectrometers were calibrated every week and transfer tubes were cleaned. A complex protein digest 
was analyzed in triplicate on the RP-LC-MS/MS platforms to validate their performance before analysis of a batch 
of samples35. LC columns were changed every 3 weeks and the solvents freshly prepared.
Computational and Bioinformatics Analysis. Computational analysis. Proteome Discoverer (version 
1.4, Thermo Scientific) was used as data processing interface. Identification was performed against the human 
UniProtKB/Swiss-Prot database (24/07/2013 or 08/12/2014 releases) including the LACB sequence (20268 and 
20194 sequences in total, respectively). Mascot (version 2.4.0 or 2.4.2, Matrix Sciences, London, UK) was used as 
search engine. Variable amino acid modifications were oxidized methionine, deamidated asparagine/glutamine, 
and sixplex TMT-labeled peptide amino terminus. Sixplex TMT-labeled lysine was set as fixed modifications as 
well as carbamidomethylation of cysteine. Trypsin was selected as the proteolytic enzyme, with a maximum of 
two potential missed cleavages. Peptide and fragment ion tolerances were set to, respectively, 10 ppm and 0.02 Da. 
All Mascot result files were loaded into Scaffold Q + 4.2.1 or 4.4.3 (Proteome Software, Portland, OR, USA) to be 
further searched with X! Tandem. Both peptide and protein FDRs were fixed at 1%, with a two unique peptide 
criterion to report protein identification. MS data quality was monitored by assessing in the samples the consist-
ence of proteome coverage and precision and trueness of LACB relative quantification as previously reported3. 
Problematic samples were flagged (for possible removal from the following bioinformatic analysis) but no batch 
(i.e., plate) issue was detected during both studies according to such type of criterion36. Relative quantitative 
protein values were exported from Scaffold Q+ as Log2 of the protein ratio fold-changes with respect to their 
measurements in the biological reference, i.e., mean Log2 values after isotopic purity correction but without nor-
malization applied between samples and experiments. The biological references were pools of individual plasma 
samples.
Bioinformatic analysis. Statistical analysis was performed using the statistical language and environment R37. In 
particular, the function rcorr form the Hmisc package and the function knnImputation from the DMwR package 
were used.
Clinical variables were presented as mean ± SD, and protein measurements in Log2 ratios respective to pool 
of samples. For the comparison of the SD of proteins (Fig. 2B), data was filtered with a 5% maximum missing 
value threshold and data was imputed using the weighted KNN imputation algorithm38, method weighted average 
(Euclidean distance to neighbours being used as weights), k = 15, where this value was chosen as it was the num-
ber of neighbours that minimized the RSS average of 1000 iterations of the complete datasets having randomly 
removed 5 percent of their data values, performed KNNImputation for k ranging from 1 to 50 neighbours (plots 
shown in Supplementary Material, Supp. Fig. S9). In order to determine gender-specific proteins (Fig. 2F-H), 
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proteins with a maximum of 30% missing values were kept and no imputation was performed. This increased 
tolerance was applied in order to include all proteins that may mostly be present in one of the genders. For the 
identification of potential confounding factors between plasma proteins levels and clinical variables, we used 
linear models as follows: the linear models used to determine the relationship between plasma protein levels and 
clinical variables (results shown in Tables 2–4 and in Supp. Figs S1 and S2) were described using the following 
relationship: (1) Prot_i ~ Age + Gender + BMI, for every protein39. P-values were adjusted for multiple testing 
using the Benjamini-Hochberg correction40. The Spearman correlations shown in Fig. 3 and Supp. Figs S3 and 
S4, were computed between clinical variables Clinical_Variable_j and e_i, where e_i are the residuals of model 
(2) Prot_i ~ Age + Gender. P-values were corrected using the Benjamini-Hochberg (BH). Significance was set at 
BH-corrected p-values less than 0.05.
Ethics. The studies were approved by local ethical committees in the respective countries. For C1: Ottawa 
Health Science Network Research Ethics Board and for C2: the Medical Ethics Committee of the University 
Hospital Maastricht and Maastricht University, the Netherlands; the Committees on Biomedical Research Ethics 
for the Capital region of Denmark, Denmark; the Suffolk Local Research Ethics Committee, United Kingdom; the 
University of Crete Ethics Committee, Greece; the Ethics Commission of the University of Potsdam, Germany; 
the Research Ethics Committee at the University of Navarra, Spain; the Ethical Committee of the Institute of 
Endocrinology, Czech Republic; and the Ethical Committee to the National Transport Multiprofile Hospital 
in Sofia, Bulgaria. For both cohorts, the Cantonal Ethics Committee for Research on Human Beings, Vaud, 
Switzerland approved the study protocol to be performed at the Nestlé Institute of Health Sciences. All study 
participants (and for the children who are not legally to sign also the parents) signed an informed consent doc-
ument after verbal and written instructions, and according to local legislation. All methods were performed in 
accordance with the relevant guidelines and regulations.
Data Availability
The MS proteomic data have been deposited to the ProteomeXchange Consortium via the PRIDE41 partner re-
pository with the dataset identifier PXD009350 (project https://doi.org/10.6019/PXD009350) for C1. The data 
were previously deposited with the dataset identifier PXD005216 for C2. The datasets used and/or analyzed dur-
ing the current study are available from the corresponding author upon request and ethical approval.
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